Skip to Main Content
Table 3.

OR and 95% CI values of prostate cancer for T. vaginalis antibody serostatus in 691 matched pairs nested in the Health Professionals Follow-up Study, 1993 to 2000

Seronegative
Seropositive
Cases/controlsOR (95% CI)Cases/controlsOR (95% CI)*Multivariable-adjusted OR (95% CI)*,
Total prostate cancer 604/626 1.00 87/65 1.41 (0.99-2.00) 1.43 (1.00-2.03) 
Organ-confined (≤T2 and N0M0440/455 1.00 67/52 1.35 (0.91-2.00) 1.36 (0.92-2.02) 
Low-grade (Gleason sum <7) 333/342 1.00 47/38 1.30 (0.81-2.09) 1.27 (0.79-2.06) 
High-grade (Gleason sum ≥7) 210/222 1.00 33/21 1.67 (0.93-2.99) 1.76 (0.97-3.18) 
Seronegative
Seropositive
Cases/controlsOR (95% CI)Cases/controlsOR (95% CI)*Multivariable-adjusted OR (95% CI)*,
Total prostate cancer 604/626 1.00 87/65 1.41 (0.99-2.00) 1.43 (1.00-2.03) 
Organ-confined (≤T2 and N0M0440/455 1.00 67/52 1.35 (0.91-2.00) 1.36 (0.92-2.02) 
Low-grade (Gleason sum <7) 333/342 1.00 47/38 1.30 (0.81-2.09) 1.27 (0.79-2.06) 
High-grade (Gleason sum ≥7) 210/222 1.00 33/21 1.67 (0.93-2.99) 1.76 (0.97-3.18) 

NOTE: Too few participants were diagnosed with advanced-stage prostate cancer (n = 62) to investigate its association with T. vaginalis antibody serostatus.

*

Estimated by conditional logistic regression.

Adjusted for race (Caucasian, non-Caucasian) and cumulative family history of prostate cancer through 1996 (yes/no).

Close Modal

or Create an Account

Close Modal
Close Modal